This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (195)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Adverse Effects  • Alert me on articles by topic

Karen E. Lasser, MD,MPH; Paul D. Allen, MD,MPH; Steffie J. Woolhandler, MD,MPH; David U. Himmelstein, MD; Sidney M. Wolfe, MD; David H. Bor, MD

JAMA. 2002;287:2215-2220.

Context  Recently approved drugs may be more likely to have unrecognized adverse drug reactions (ADRs) than established drugs, but no recent studies have examined how frequently postmarketing surveillance identifies important ADRs.

Objective  To determine the frequency and timing of discovery of new ADRs described in black box warnings or necessitating withdrawal of the drug from the market.

Design and Setting  Examination of the Physicians' Desk Reference for all new chemical entities approved by the US Food and Drug Administration between 1975 and 1999, and all drugs withdrawn from the market between 1975 and 2000 (with or without a prior black box warning).

Main Outcome Measures  Frequency of and time to a new black box warning or drug withdrawal.

Results  A total of 548 new chemical entities were approved in 1975-1999; 56 (10.2%) acquired a new black box warning or were withdrawn. Forty-five drugs (8.2%) acquired 1 or more black box warnings and 16 (2.9%) were withdrawn from the market. In Kaplan-Meier analyses, the estimated probability of acquiring a new black box warning or being withdrawn from the market over 25 years was 20%. Eighty-one major changes to drug labeling in the Physicians' Desk Reference occurred including the addition of 1 or more black box warnings per drug, or drug withdrawal. In Kaplan-Meier analyses, half of these changes occurred within 7 years of drug introduction; half of the withdrawals occurred within 2 years.

Conclusions  Serious ADRs commonly emerge after Food and Drug Administration approval. The safety of new agents cannot be known with certainty until a drug has been on the market for many years.

Author Affiliations: Department of Medicine, Cambridge Hospital and Harvard Medical School, Cambridge, Mass (Drs Lasser, Allen, Woolhandler, Himmelstein, and Bor); and Public Citizen Health Research Group, Washington, DC (Dr Wolfe).

RELATED LETTERS

Postprandial Hyperglycemia and Risk of Atherosclerosis
Nasser Mikhail, Joshua A. Beckman, Mark A. Creager, and Peter Libby
JAMA. 2002;288(8):955.
EXTRACT | FULL TEXT  

Postmarketing Surveillance and Black Box Warnings
Garth K. Graham, Anthony K. Wutoh, Rita D. Wutoh, J. P. Hampson, J. N. Harvey, Stephen A. Goldman, Penelope J. Greene, Theodore J. La Vaque, Karen E. Lasser, Steffie J. Woolhandler, David U. Himmelstein, Sidney M. Wolfe, Robert J. Temple, and Martin H. Himmel
JAMA. 2002;288(8):955-959.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Safety of Newly Approved Drugs: Implications for Prescribing
Robert J. Temple and Martin H. Himmel
JAMA. 2002;287(17):2273-2275.
EXTRACT | FULL TEXT  

May 1, 2002
JAMA. 2002;287(17):2295-2296.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity
Smith et al.
Pediatrics 2008;122:e628-e633.
ABSTRACT | FULL TEXT  

CUTRONA ET AL. RESPOND
Cutrona et al.
Am. J. Public Health 2008;98:1349-1349.
FULL TEXT  

Direct-to-consumer advertising: end the compromise
Hebert
CMAJ 2008;179:119-119.
FULL TEXT  

La publicite directe au consommateur : fini les compromis
Hebert
CMAJ 2008;179:121-121.
FULL TEXT  

High free thyroxine levels are associated with QTc prolongation in males
van Noord et al.
J Endocrinol 2008;198:253-260.
ABSTRACT | FULL TEXT  

Application of a High-Content Multiparameter Cytotoxicity Assay to Prioritize Compounds Based on Toxicity Potential in Humans
Abraham et al.
J Biomol Screen 2008;13:527-537.
ABSTRACT  

Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and Genotoxicity Studies
Josse et al.
Drug Metab. Dispos. 2008;36:1111-1118.
ABSTRACT | FULL TEXT  

Drug-Review Deadlines and Safety Problems
Carpenter et al.
NEJM 2008;358:1354-1361.
ABSTRACT | FULL TEXT  

"Torsade"
Keller and Lemberg
Am J Crit Care 2008;17:77-81.
FULL TEXT  

Direct-To-Consumer Advertisements For HIV Antiretroviral Medications: A Progress Report
Kallen et al.
Health Aff (Millwood) 2007;26:1392-1398.
ABSTRACT | FULL TEXT  

Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
Strevel et al.
JCO 2007;25:3362-3371.
ABSTRACT | FULL TEXT  

The Record on Rosiglitazone and the Risk of Myocardial Infarction
Psaty and Furberg
NEJM 2007;357:67-69.
FULL TEXT  

Ethical Issues in Stopping Randomized Trials Early Because of Apparent Benefit
Mueller et al.
ANN INTERN MED 2007;146:878-881.
ABSTRACT | FULL TEXT  

Benefits of ADHD drugs may trump concerns over potential risks
McAbee
AAP News 2007;28:18-19.
FULL TEXT  

Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers
Bennett et al.
Arch Intern Med 2007;167:1041-1049.
ABSTRACT | FULL TEXT  

What's More Dangerous, Your Aspirin Or Your Car? Thinking Rationally About Drug Risks (And Benefits)
Cohen and Neumann
Health Aff (Millwood) 2007;26:636-646.
ABSTRACT | FULL TEXT  

POSTMARKETING MODIFICATIONS IN THE SAFETY LABELING OF THE NEW ANTIEPILEPTICS
Buck et al.
Neurology 2007;68:1536-1537.
FULL TEXT  

PDUFA Reauthorization -- Drug Safety's Golden Moment of Opportunity?
Hennessy and Strom
NEJM 2007;356:1703-1704.
FULL TEXT  

The Effect of Antidepressant Warnings on Prescribing Trends in Ontario, Canada
Kurdyak et al.
Am. J. Public Health 2007;97:750-754.
ABSTRACT | FULL TEXT  

Adverse Drug Reactions Among Children Over a 10-Year Period
Le et al.
Pediatrics 2006;118:555-562.
ABSTRACT | FULL TEXT  

A safety assessment tool for formulary candidates.
Pick et al.
Am J Health Syst Pharm 2006;63:1269-1272.
FULL TEXT  

Disseminating Drug Prescribing Information: The Cox-2 Inhibitors Withdrawals
Strayer et al.
J. Am. Med. Inform. Assoc. 2006;13:396-398.
ABSTRACT | FULL TEXT  

Re-examining our approach to the approval and use of new drugs.
Lee
CMAJ 2006;174:1855-1855.
FULL TEXT  

How the US drug safety system should be changed.
Strom
JAMA 2006;295:2072-2075.
FULL TEXT  

Defining the phases of clinical trials
Nguyen et al.
Am J Health Syst Pharm 2006;63:710-711.
FULL TEXT  

Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies
Papanikolaou et al.
CMAJ 2006;174:635-641.
ABSTRACT | FULL TEXT  

Adverse events: the more you search, the more you find.
Ioannidis et al.
ANN INTERN MED 2006;144:298-300.
FULL TEXT  

Adherence to black box warnings for prescription medications in outpatients.
Lasser et al.
Arch Intern Med 2006;166:338-344.
ABSTRACT | FULL TEXT  

Medication-Attributed Adverse Effects in Placebo Groups: Implications for Assessment of Adverse Effects
Rief et al.
Arch Intern Med 2006;166:155-160.
ABSTRACT | FULL TEXT  

Patient- and Facility-Level Factors Associated With Diffusion of a New Antipsychotic in the VA Health System
Valenstein et al.
Psychiatr. Serv. 2006;57:70-76.
ABSTRACT | FULL TEXT  

SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING
Smith and Obach
Drug Metab. Dispos. 2005;33:1409-1417.
ABSTRACT | FULL TEXT  

Improved Perioperative Outcomes From Carotid Endarterectomy: Yet Another Statin Side Effect?
Kent
Stroke 2005;36:2058-2059.
FULL TEXT  

Autonomy, consent, and limiting healthcare costs
Graber and Tansey
J. Med. Ethics 2005;31:424-426.
ABSTRACT | FULL TEXT  

Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002: The Importance of Reporting Suspected Reactions
Wysowski and Swartz
Arch Intern Med 2005;165:1363-1369.
ABSTRACT | FULL TEXT  

Challenges in Systematic Reviews That Assess Treatment Harms
Chou and Helfand
ANN INTERN MED 2005;142:1090-1099.
ABSTRACT | FULL TEXT  

The Role of the Pharmaceutical Industry in Teaching Psychopharmacology: A Growing Problem
Brodkey
Acad. Psychiatry 2005;29:222-229.
ABSTRACT | FULL TEXT  

The Research on Adverse Drug Events and Reports (RADAR) Project
Bennett et al.
JAMA 2005;293:2131-2140.
ABSTRACT | FULL TEXT  

Direct-to-Consumer Advertising: A Haphazard Approach to Health Promotion
Hollon
JAMA 2005;293:2030-2033.
FULL TEXT  

Potential Utility of Data-Mining Algorithms for Early Detection of Potentially Fatal/Disabling Adverse Drug Reactions: A Retrospective Evaluation
Hauben and Reich
J Clin Pharmacol 2005;45:378-384.
ABSTRACT | FULL TEXT  

Drug withdrawals from the Canadian market for safety reasons, 1963-2004
Lexchin
CMAJ 2005;172:765-767.
FULL TEXT  

The Impact of New Drug Introduction on Drug Expenditure in Primary Health Care in Catalunya, Spain
Zara et al.
The Annals of Pharmacotherapy 2005;39:177-182.
ABSTRACT | FULL TEXT  

Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis
Psaty et al.
JAMA 2004;292:2622-2631.
ABSTRACT | FULL TEXT  

Antidepressants: An Avoidable and Solvable Controversy
Cohen
The Annals of Pharmacotherapy 2004;38:1743-1746.
FULL TEXT  

Complementary and Alternative Health Care and the Home Care Population
Cushman and Hoffman
Home Health Care Management Practice 2004;16:360-373.
ABSTRACT  

Collecting and sharing information about harms
Pirmohamed and Darbyshire
BMJ 2004;329:6-7.
FULL TEXT  

Comparing Dexmedetomidine Prescribing Patterns and Safety in the Naturalistic Setting Versus Published Data
Dasta et al.
The Annals of Pharmacotherapy 2004;38:1130-1135.
ABSTRACT | FULL TEXT  

On the relative safety of parenteral iron formulations
Chertow et al.
Nephrol Dial Transplant 2004;19:1571-1575.
ABSTRACT | FULL TEXT  

Efficacy and safety of antidepressants for children and adolescents
Jureidini et al.
BMJ 2004;328:879-883.
FULL TEXT  

Drug-Induced Prolongation of the QT Interval
Roden
NEJM 2004;350:1013-1022.
FULL TEXT  

Gaps, Tensions, and Conflicts in the FDA Approval Process: Implications for Clinical Practice
Deyo
J Am Board Fam Med 2004;17:142-149.
ABSTRACT | FULL TEXT  

Clopidogrel-Associated TTP: An Update of Pharmacovigilance Efforts Conducted by Independent Researchers, Pharmaceutical Suppliers, and the Food and Drug Administration
Zakarija et al.
Stroke 2004;35:533-537.
ABSTRACT | FULL TEXT  

Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project
Ladewski et al.
JCO 2003;21:3859-3866.
ABSTRACT | FULL TEXT  

Canadian and US Drug Approval Times and Safety Considerations
Rawson and Kaitin
The Annals of Pharmacotherapy 2003;37:1403-1408.
ABSTRACT | FULL TEXT  

Pneumonitis with Antiandrogens
Bennett and Sartor
ANN INTERN MED 2003;139:529-529.
FULL TEXT  

Direct-to-consumer prescription drug advertising in Canada: Permission by default?
Gardner et al.
CMAJ 2003;169:425-427.
FULL TEXT  

Improving Medication Use for Older Adults: An Integrated Research Agenda
Murray and Callahan
ANN INTERN MED 2003;139:425-429.
ABSTRACT | FULL TEXT  

Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France
Wiktorowicz
Journal of Health Politics, Policy and Law 2003;28:615-658.
ABSTRACT  

Drug-Induced Hepatotoxicity
Lee
NEJM 2003;349:474-485.
FULL TEXT  

Commentary: Making "Me-too" Drugs Benefit the Public
Nusbaum
American Journal of Medical Quality 2002;17:215-217.
ABSTRACT  

Discontinuation of thioridazine
Bisset et al.
BMJ 2002;325:967-967.
FULL TEXT  

COX-2 inhibitors in the treatment of cardiovascular disease
Sztuke-Fournier and McMorran
CMAJ 2002;167:739-740.
FULL TEXT  

Polypharmacy: Boon or Bane for Health Care Providers?: Preface
McCloskey
Diabetes Spectr. 2002;15:237-239.
FULL TEXT  

Postmarketing Surveillance and Black Box Warnings
Graham et al.
JAMA 2002;288:955-959.
FULL TEXT  

Market Withdrawal of Prescription Drugs
JWatch Psychiatry 2002;2002:12-12.
FULL TEXT  

Market Withdrawal of Prescription Drugs
JWatch General 2002;2002:9-9.
FULL TEXT  

Safety of Newly Approved Drugs: Implications for Prescribing
Temple and Himmel
JAMA 2002;287:2273-2275.
FULL TEXT